布地奈德＋孟鲁司特治疗轻中度持续哮喘的临床疗效观察

目的：探讨布地奈德在轻中度持续哮喘治疗中的临床应用价值。方法：将2010年6月—2011年6月收治的100例轻中度持续哮喘患者以随机抽样法分成观察组与对照组各50例,对照组采用孟鲁司特钠口服治疗,观察组采用布地奈德＋孟鲁司特联合治疗。观察比较治疗后2组间患者临床疗效、不良反应发生情况、平均住院时间与呼吸困难、喘息、哮鸣音、咳嗽消失时间及肺功能、哮喘症状评分。结果：观察组总有效率为96.0%（48/50）,对照组总有效率为76.0%（38/50）,观察组患者的临床疗效显著优于对照组（P〈0.05）;观察组患者的平均住院时间与呼吸困难、喘息、哮鸣音、咳嗽消失时间均明显少于对照组（P〈0.05）;观察组患者的肺功能改善程度和哮喘症状评分均明显优于对照组（P〈0.05）;观察组患者心肺功能参数改善明显优于对照组（P〈0.05）;观察组与对照组在治疗费用和抗菌药物使用数量、时间方面比较,差异有统计学意义（P〈0.05）。结论：临床应用布地奈德＋孟鲁司特联合治疗轻中度持续哮喘的效果良好。

Clinical Efficacy of Budesonide Plus Montelukast for Mild-to-Moderate Persistent Asthma

OBJECTIVE：To investigate the clinical application value of budesonide in the treatment of mild-to- moderate persistent asthma. METHODS： 100 patients with mild-to-moderate continuous asthma treated in our hospital from June 2010 to June 2011 were randomly assigned to receive either montelukast sodium alone （control group） or montelukast sodium plus budesonide （ experimental group） of 50 cases each. The two groups were compared with regard to clinical efficacy, adverse reactions, average length of hospital stay, time to extinction of dyspnea, wheeze, cough and wheezing rale, lung function and asthma symptom scores. RESULTS： The total effective rate in the experimental group was significantly higher than in the control group 96.0% （48/50） vs. 76.0% （38/50, P 〈 0.05） ; the average length of hospital stay, time to distinction of dyspnea, wheeze, cough and wheezing rale were significantly less in the experimental group than in the control group （ P 〈 0.05 ） ; the experimental group had better improvement in pulmonary function and asthma symptom scores （ P 〈 0.05 ） and cardiopulmonary function parameters than in the control group （ P 〈 0. 05 ）. The differences between the experimental group and control group in treatmentcosts, number of antibiotics CONCLUSION： Treatment of satisfactory curative efficacy. used and duration of antibiotic use were statistically significant （P mild-to-moderate continuous asthma with budesonide plus montelukast 〈 0.05 ）. resulted in